Key facts
- This page summarizes Eric A. Rose MD's Form 4 filing for ABIOMED INC.
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2022, 16:05.
Eric A. Rose MD - 10 Aug 2022 Form 4 Insider Report for ABIOMED INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 10 Aug 2022
- Net transaction value
- -$91,815
- SEC form
- 4
- Accepted by SEC
- 12 Aug 2022, 16:05:52 UTC
- Prior SEC filing
- 13 Aug 2021
- Next SEC filing
- 30 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc A Began (by power of attorney)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric A. Rose MD filed Form 4 for ABIOMED INC on 12 Aug 2022.
Change
- Previous filing in this sequence was filed on 13 Aug 2021.
- Current net transaction value: -$91,815.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NASD
transaction
Common Stock, $.01 par value
Award
- Transaction value
- $0
- Shares
- +681
- Change %
- +4.6%
- Price
- $0.000000
- Shares after
- 15,516
- Date
- 10 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
NASD
transaction
Common Stock, $.01 par value
Tax liability
- Transaction value
- $91,815
- Shares
- -313
- Change %
- -2%
- Price
- $293.34
- Shares after
- 15,203
- Date
- 11 Aug 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the earlier of: (a) the first anniversary of the date of grant; and (b) the date of the Corporation's 2023 Annual Meeting; that such awards shall be subject to a -Restricted Stock Unit Award Agreement in accordance with the Second Amended & Restated 2015 Omnibus Incentive Plan.
Footnote F2
Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards.